摘要目的 探讨格列齐特联合阿卡波糖治疗2型糖尿病（T2DM）的临床效果。方法 选取2019年6月～2020年7月阳江市阳东区人民医院收治的100 例T2DM 患者作为研究对象，采用随机数字表法将其分为对照组与观察组，每组各50 例。对照组患者给予阿卡波糖治疗，观察组患者在对照组的基础上联合格列齐特治疗，疗程为12周。比较治疗前及治疗后两组患者的空腹血糖（FPG）、餐后2 h 血糖（2 h PG）、糖化血红蛋白（HbA1c）、血清超敏C 反应蛋白（hs-CRP）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平及治疗期间不良反应发生情况。结果 治疗前两组患者的FPG、2 h PG、HbA1c 水平比较，差异无统计学意义（P＞0.05）；治疗后两组患者的FPG、2 h PG、HbA1c水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。治疗前两组患者的hs-CRP、IL-6、TNF-α 水平比较，差异无统计学意义（P＞0.05）；治疗后两组患者hs-CRP、IL-6、TNF-α 水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论 格列齐特联合阿卡波糖治疗T2DM 可有效降低FPG、2 h PG、HbA1c、hs-CRP、IL-6、TNF-α 水平，不增加不良反应。
Abstract：Objective To explore the clinical effect of Gliclazide combined with Acarbose in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 100 cases of T2DM patients admitted to the People′s Hospital of Yangdong District in Yangjiang City from June 2019 to July 2020 were selected as the research objects.According to random number table method,they were divided into the control group and the observation group,with 50 cases in each group.The control group was given Acarbose treatment,while the observation group was given Gliclazide on the basis of the control group.The course of treatment was 12 weeks.The levels of fasting blood glucose(FPG),2 h postprandibular blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),serum hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and the incidence of adverse reactions during treatment were compared between the two groups before and after treatment.Results There were no statistically significant differences in the levels of FPG,2 h PG and HbA1c between the two groups before treatment(P＞0.05).After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were lower than those before treatment,and the levels of FPG,2 h PG and HbA1c in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).There were no statistically significant differences in the levels of hs-CRP,IL-6 and TNF-α between the two groups before treatment(P＞0.05).After treatment,the levels of hs-CRP,IL-6 and TNF-α of the two groups were lower than those before treatment,and the levels of hs-CRP,IL-6 and TNF-α of the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Gliclazide combining with Acarbose in the treatment of T2DM can effectively reducing the levels of FPG,2 h PG,HbA1c,hs-CRP,IL-6 and TNF-α,without increasing the adverse reactions.
谭秋玲;罗小静;陈俏蓉. 格列齐特联合阿卡波糖治疗2型糖尿病的临床效果[J]. 中国当代医药, 2021, 28(17): 64-66转70.
TAN Qiu-ling; LUO Xiao-jing ;CHEN Qiao-rong. Clinical effect of Gliclazide combined with Acarbose in the treatment of type 2 diabetes mellitus. 中国当代医药, 2021, 28(17): 64-66转70.
京公网安备 11010502046607号